enGene, Inc.
Nasdaq ENGN · Saint-Laurent, Quebec, Canada
Works in Oncology · Renal & urogenital · Women's health
enGene, Inc. is a clinical trial sponsor based in Saint-Laurent, Quebec, Canada, listed as Nasdaq ENGN. It has 1 active clinical trial with 350 planned participants, in Oncology, Renal & urogenital and Women's health.
Trial track record · since 2021
Financials · Nasdaq ENGN
Fundraising
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about enGene, Inc
enGene, Inc is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 350 planned participants, in Oncology, Renal & urogenital, Women's health. Since 2021 it has completed 0 trials and stopped 0 early.
enGene, Inc is based in Saint-Laurent, Quebec, Canada and is listed as Nasdaq ENGN. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with enGene, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-07.
Approve Suite is not affiliated with enGene, Inc.. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.